S&P 500   4,234.92 (-1.14%)
DOW   33,773.07 (-0.66%)
QQQ   322.52 (-2.05%)
AAPL   171.96 (-1.26%)
MSFT   285.98 (-1.44%)
META   167.83 (-3.91%)
GOOGL   117.00 (-2.64%)
AMZN   138.20 (-2.88%)
TSLA   883.13 (-2.80%)
NVDA   178.09 (-5.14%)
NIO   19.06 (-4.27%)
BABA   89.44 (-1.43%)
AMD   94.82 (-5.60%)
T   18.42 (-0.05%)
MU   60.49 (-3.95%)
CGC   3.79 (-0.52%)
F   15.82 (-2.04%)
GE   77.56 (-2.08%)
DIS   120.15 (-2.05%)
AMC   17.90 (-7.21%)
PYPL   96.79 (-3.07%)
PFE   49.32 (+1.52%)
NFLX   237.95 (-2.94%)
S&P 500   4,234.92 (-1.14%)
DOW   33,773.07 (-0.66%)
QQQ   322.52 (-2.05%)
AAPL   171.96 (-1.26%)
MSFT   285.98 (-1.44%)
META   167.83 (-3.91%)
GOOGL   117.00 (-2.64%)
AMZN   138.20 (-2.88%)
TSLA   883.13 (-2.80%)
NVDA   178.09 (-5.14%)
NIO   19.06 (-4.27%)
BABA   89.44 (-1.43%)
AMD   94.82 (-5.60%)
T   18.42 (-0.05%)
MU   60.49 (-3.95%)
CGC   3.79 (-0.52%)
F   15.82 (-2.04%)
GE   77.56 (-2.08%)
DIS   120.15 (-2.05%)
AMC   17.90 (-7.21%)
PYPL   96.79 (-3.07%)
PFE   49.32 (+1.52%)
NFLX   237.95 (-2.94%)
S&P 500   4,234.92 (-1.14%)
DOW   33,773.07 (-0.66%)
QQQ   322.52 (-2.05%)
AAPL   171.96 (-1.26%)
MSFT   285.98 (-1.44%)
META   167.83 (-3.91%)
GOOGL   117.00 (-2.64%)
AMZN   138.20 (-2.88%)
TSLA   883.13 (-2.80%)
NVDA   178.09 (-5.14%)
NIO   19.06 (-4.27%)
BABA   89.44 (-1.43%)
AMD   94.82 (-5.60%)
T   18.42 (-0.05%)
MU   60.49 (-3.95%)
CGC   3.79 (-0.52%)
F   15.82 (-2.04%)
GE   77.56 (-2.08%)
DIS   120.15 (-2.05%)
AMC   17.90 (-7.21%)
PYPL   96.79 (-3.07%)
PFE   49.32 (+1.52%)
NFLX   237.95 (-2.94%)
S&P 500   4,234.92 (-1.14%)
DOW   33,773.07 (-0.66%)
QQQ   322.52 (-2.05%)
AAPL   171.96 (-1.26%)
MSFT   285.98 (-1.44%)
META   167.83 (-3.91%)
GOOGL   117.00 (-2.64%)
AMZN   138.20 (-2.88%)
TSLA   883.13 (-2.80%)
NVDA   178.09 (-5.14%)
NIO   19.06 (-4.27%)
BABA   89.44 (-1.43%)
AMD   94.82 (-5.60%)
T   18.42 (-0.05%)
MU   60.49 (-3.95%)
CGC   3.79 (-0.52%)
F   15.82 (-2.04%)
GE   77.56 (-2.08%)
DIS   120.15 (-2.05%)
AMC   17.90 (-7.21%)
PYPL   96.79 (-3.07%)
PFE   49.32 (+1.52%)
NFLX   237.95 (-2.94%)
OTCMKTS:NPHC

Nutra Pharma - NPHC Stock Forecast, Price & News

$0.0008
0.00 (0.00%)
(As of 08/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.00
$0.00
50-Day Range
N/A
52-Week Range
$0.00
$0.01
Volume
N/A
Average Volume
155,256 shs
Market Capitalization
$5.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NPHC stock logo

About Nutra Pharma (OTCMKTS:NPHC) Stock

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, non-narcotic, non-addictive, and over-the-counter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and anti-inflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.

Receive NPHC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nutra Pharma and its competitors with MarketBeat's FREE daily newsletter.

NPHC Stock News Headlines

Nutra Pharma signs first manufacturing agreement
Nutra Pharma Announces First Manufacturing Agreement
Nutra Pharma Expands Manufacturing Capabilities
Nutra Pharma Corp.
Nutra Pharma Letter to Shareholders
News for Nutra Pharma Corp
Nutra Pharma Provides Business and Compliance Updates
Nutra Pharma Corp. (NPHC)
See More Headlines
Receive NPHC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nutra Pharma and its competitors with MarketBeat's FREE daily newsletter.

NPHC Company Calendar

Last Earnings
8/17/2018
Today
8/19/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:NPHC
Employees
4
Year Founded
N/A

Profitability

Net Income
$-13,100,000.00
Net Margins
26,466.78%
Pretax Margin
26,465.75%

Debt

Sales & Book Value

Annual Sales
$100,000.00

Miscellaneous

Outstanding Shares
7,029,740,000
Free Float
2,706,450,000
Market Cap
$5.62 million
Optionable
Not Optionable
Beta
2.36

Key Executives

  • Mr. Erik J. Deitsch (Age 54)
    Chairman, CEO, Pres & CFO
    Comp: $130k
  • Dr. Dale VanderPutten MBA (Age 63)
    Ph.D., Chief Scientific Officer
    Comp: $144k
  • Mr. Neil Roth
    Pres of Designer Diagnostics, Inc
  • Ms. Nina Goldstein (Age 62)
    Sec.













NPHC Stock - Frequently Asked Questions

How have NPHC shares performed in 2022?

Nutra Pharma's stock was trading at $0.0020 at the beginning of the year. Since then, NPHC shares have decreased by 60.0% and is now trading at $0.0008.
View the best growth stocks for 2022 here
.

How were Nutra Pharma's earnings last quarter?

Nutra Pharma Corp. (OTCMKTS:NPHC) announced its quarterly earnings results on Friday, August, 17th. The company reported $0.00 EPS for the quarter. The firm earned $0.03 million during the quarter. Nutra Pharma had a net margin of 26,466.78% and a negative trailing twelve-month return on equity of 104.20%.

What other stocks do shareholders of Nutra Pharma own?
What is Nutra Pharma's stock symbol?

Nutra Pharma trades on the OTCMKTS under the ticker symbol "NPHC."

How do I buy shares of Nutra Pharma?

Shares of NPHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nutra Pharma's stock price today?

One share of NPHC stock can currently be purchased for approximately $0.00.

How much money does Nutra Pharma make?

Nutra Pharma (OTCMKTS:NPHC) has a market capitalization of $5.62 million and generates $100,000.00 in revenue each year.

How can I contact Nutra Pharma?

Nutra Pharma's mailing address is 12538 WEST ATLANTIC BLVD., CORAL SPRINGS FL, 33071. The official website for the company is www.nutrapharma.com. The company can be reached via phone at (954) 509-0911, via email at investor.relations@nutrapharma.com, or via fax at 877-895-5647.

This page (OTCMKTS:NPHC) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.